Tactics used by intermediaries in the pharmaceutical distribution system, including pharmacy benefit managers (PBMs) and insurers, are costing patients, employers and the government billions for what should be inexpensive medicines.
Other featured articles
The Economic Case for Federal Investment in COVID-19 Vaccines and Therapeutics Remains Strong
Schaeffer Initiative experts argue that there is a strong economic case for continued federal investment in COVID-19 vaccines and therapeutics.
Private Equity-Owned Air Ambulance Carriers Get Paid More Money and Are Out-of-Network More Often
In this analysis, we build on that prior work to document differences in allowed amounts, out-of-network prevalence, and the magnitude of potential surprise balance bills across ownership types in the helicopter air ambulance market.
Targeting Affordability in Healthcare: A Review of the Evidence
Health plans have many tools to reduce spending and therefore reduce plan premiums, which can improve the affordability of health insurance.
The 340B Drug Pricing Program: Background, Ongoing Challenges and Recent Developments
The 340B Drug Pricing Program allows eligible healthcare clinics and hospitals (“covered entities”) to purchase outpatient drugs at a 20-50% discount.